
Biocon Secures USFDA Approval for Pebrilzo, Its Fifth Cancer Biosimilar
What Happened?
Biocon Limited announced USFDA approval for Pebrilzo, a biosimilar for breast cancer treatment. This marks the company's fifth oncology biosimilar approved in the US.
Key points
- Pebrilzo is a biosimilar of Perjeta, used for HER2-positive breast cancer.
- The drug is indicated for use with trastuzumab and chemotherapy.
- Biocon's oncology portfolio includes four other approved biosimilars.
- The earliest licensed launch date for Pebrilzo in the US is set for Q3 2028.
- The approval follows a positive opinion from the European Medicines Agency.
Key insights
- The approval strengthens Biocon's position in the oncology market.
- Pebrilzo's launch may provide cost-effective treatment alternatives for patients.
- The collaboration with Genentech may facilitate smoother market entry.
Why it matters
This approval could enhance access to affordable cancer treatment options for patients.
Entities
Source
Business Standard
